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Conclusions: RT3D VCA provides an effective monitoring of immediate MR reduction
after MitraClip. EVEREST pathologies have a tendency towards better acute results with
a significantly lower need of clips.
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Background: MitraClip (MC) implantation has recently become a percutaneous option
to safely treat grade 3	/4	 mitral regurgitation (MR); long-term data are still scarce. In
patients not amenable to surgery, we assessed pertinent echocardiographic and clinical
variables out to 24 months after successful (discharge MR 2	) MC therapy.
Methods: Of 311 consecutive patients with 3	/4	MR (54%/46%) treated at our center,
2-year follow-up (FU) was due by July 1, 2012, in 133 successfully treated patients.
Forty-one (31%) of these patients had died before FU. Of 92 surviving patients, 83 (74
9 years; 52 [63%] men; 57 [69%] with functional MR) were followed for a median of 23.8
[IQR, 22.1 – 24.9] months. Transthoracic echo data as well as 6-minute walk distance
(6MWD) and Minnesota (MLHFQ) quality-of-life score were assessed at baseline (BL),
discharge (D; echo only), 6, 12, and 24 months.
Results: Significant reductions vs. BL were observed at D in regurgitant volume, left
ventricular (LV) end-diastolic volume, stroke volume, and LV ejection fraction, but not
LV end-systolic volume; all variables remained unchanged at subsequent dates. Forward
stroke volume (FSV) increased gradually from 45 ml (BL) to reach a plateau of 55 ml by
6 months (Figure, panel A). Similar improvements were observed for 6MWD (Figure,
panel B) and MLHFQ score.
Conclusions: In elderly patients with significant MR not amenable to surgery, successful
MC implantation caused immediate and apparently permanent LV reverse remodeling.
This translated into significant and sustained improvement in FSV, 6MWD and quality of
life out to 2 years.
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Background: The impact of mitral valve repair in patients with severe mitral regurgi-
tation (MR), particularly with significant LV dysfunction and comorbidities is difficult to
predict. We examined the possible long-term prognostic impact of MR.
Methods: This was a match case-control study that recruited 532 patients from a
single-centre echocardiographic database. Patients were matched in a 1:1 fashion (216
with moderate/severe MR and 216 with no/mild MR) adjusting for age, gender, LV
function and echocardiogram date. Baseline characteristics were compared between both
groups. The association between significant MR and event-free survival was plotted using
Kaplan Meier methods. Using a Royston-Parmer (RP) survival model, 15-year outcomes
were predicted to estimate the average number of years lost due to MR and the potential
life-years added from mitral valve repair.
Results: Both groups were well matched for age, gender, LV function, ischaemic heart
disease, hypertension and diabetes. Significant MR was associated with increased
12-month and overall mortality (18% vs. 31%, p  0.012 and 35.6% vs. 46.4%, p 
0.015 respectively). Cox proportional hazard analysis demonstrated increased risk of
death with significant MR (HR 1.66; 95% CI 1.04-2.62, p  0.031), ejection fraction 
30% (HR;1.61; 95% CI; 1.03-2.16, p  0.039), COPD (HR 1.95; CI 1.35-2.85, p 
0.001) and renal dysfunction (HR 2.11; CI 1.45-3.07, p  0.001). RP plots were well
matched with observed mortality from this and published studies over 12-month periods.
A RP plot of 65 year olds with normal LV function and severe MR predicted a median
survival of 4.87 years with the potential to gain 1.6 life-years over 15-years following
correction of MR. RP plots of 70 year olds with severe MR, LVD and renal dysfunction
predicted a median survival of 2.6 years with the potential to gain 1.0 life years.
Conclusions: Mitral regurgitation remains undertreated and is associated with indepen-
dent prognostic significance. The Royston-Parmer model represents a potentially useful
risk stratification tool, which may have significant implications for patient selection and
funding discussions for the future application of novel devices for the treatment of MR.
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Background: Up to 10% of patients (pts) undergoing valvular replacement will develop
paravalvular leaks (PVL) which can result in significant hemolysis (HL) or congestive
heart failure (CHF). Many pts are at very high risk for re-operation. Transcatheter
occlusion represents an attractive alternative to surgery for PVL.
Methods: Between June 01 and December 10, 56 consecutive pts underwent 61
percutaneous attempts of PVL repair in our institution. PVL closure procedures were
initially performed with the Amplatzer Duct Occluder (St Jude Medical, Maple Grove,
MN) device followed by the Amplatzer mVSD Occluder device since 05 and/or
Amplatzer Vascular Plug III device since 08. Clinical and procedural data were analysed.
Technical success was defined as an immediate decrease in  one grade of regurgitation
without intra-procedural complication. Pt follow-up was performed by questionnaire; all
events were verified by case record review.
Results: Pt mean age was 64.911, 51.7% were male, mean logistic EuroSCORE was
18.7514%. Mean number of previous surgery was 2.44 and mean interval between last
surgery and PVL repair was 92.881.6 months. Indications included CHF (61%), HL
(9%), or both (30%), for mitral mechanical (n39), mitral bioprosthetic (n5), aortic
mechanical (n11) and aortic bioprosthesis (n1) PVL. Device implantation was
successful in 46 procedures (75.4%) involving 42 patients (75%) and technical success
was achieved in 43 of the 61 procedures (70.5%). Two patients had initial prosthetic valve
obstruction corrected by immediate percutaneous device retrieval. Three major compli-
cations including 2 deaths happened during the 30-day follow-up in the 42 pts who
received a device. Mean follow-up was 2927 months. Overall 6 pts (14%) required a
surgical redo after successful initial device deployement. Multivariable analysis showed
that successful PVL repair was associated with a survival free of death, rehospitalisation
for CHF or surgical redo (HR 0.34, 95% CI [0.15-0.62]).
Conclusions: Transcatheter PVL reduction is a promising alternative to redo surgery and
should be considered for the challenging clinical problem of PVL in high-risk patients.
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